Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

Novartis Kisqali® Data Show Superior Overall Survival Compared To Fulvestrant And Consistent Efficacy Across Advanced Breast Cancer Patient Subgroups In MONALEESA-3

(Novartis) Dec 11, 2019 - MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results for Kisqali plus fulvestrant, reducing the risk of death by almost 30%.

U.S. Watchdog Finds $6.7 Billion In Questionable Medicare Payments To Insurers

(Reuters) Dec 12, 2019 - A U.S. government watchdog is raising fresh concerns that health insurers are exaggerating how sick Medicare patients are, receiving billions of dollars in improper payments as a result.

First-line Nivolumab Plus Chemotherapy Did Not Meet the Primary Endpoint of Overall Survival in Non-Squamous NSCLC

(ESMO I-O 2019) Dec 12, 2019 - Results of the CheckMate 227 - part 2 final analysis.

Teos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with KEYTRUDA®

(iTeos) Dec 12, 2019 - iTeos Therapeutics SA announced today that it has entered into an agreement with a subsidiary of Merck, known as MSD outside the United States and Canada, to evaluate the safety and efficacy of EOS100850, iTeos’ investigational A2A receptor antagonist, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy, in patients with solid tumors.

Novartis Still Hasn’t Solved Its CAR-T Manufacturing Issues

(BioPharma Dive) Dec 12, 2019 - Novartis has shipped CAR-T cell therapies to about 1,800 people with blood cancer, a noteworthy accomplishment for a personalized product made from patients' own immune cells.

First-line Nivolumab Plus Ipilimumab is Safe and Provides Encouraging Survival in Patients with Advanced NSCLC and Co-Morbidity or Poor Performance Status

(ESMO I-O 2019) Dec 12, 2019 - Nivolumab plus ipilimumab is effective regardless of PD-L1 expression levels in advanced NSCLC.

Research Brief: Discovering How People With Breast Cancer Use Facebook For Support

(University of Minnesota) Dec 11, 2019 - A study by the University of Minnesota School of Public Health recently analyzed the activity of breast cancer survivors on Facebook during their treatment and found while they posted more, they made relatively few requests for help.

Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy

(Gilead) Dec 11, 2015 - Kite, a Gilead Company, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the investigational chimeric antigen receptor (CAR) T cell therapy, KTE-X19, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The BLA submission is based on data from the Phase 2 ZUMA-2 trial, which demonstrated an overall response rate of 93 percent, including 67 percent with complete response, as assessed by an Independent Radiologic Review Committee (IRRC) following a single infusion of KTE-X19. In the safety analysis, Grade 3 or higher cytokine release syndrome (CRS) and neurologic events were seen in 15 percent and 31 percent of patients, respectively. No Grade 5 CRS or neurologic events occurred. Detailed findings from this trial were recently presented at the 61stAmerican Society of Hematology (ASH) Annual Meeting & Exposition in Orlando.

FDA Warns Company Over Ad That Leaves Out Information On Risk Of Overdose

(Washington Post) Dec 12, 2019 - The Food and Drug Administration has warned the manufacturer of a long-acting anti-addiction medication that its printed advertisement does not include one of the most serious risks of using the product: the increased chance of an opioid overdose.

First-Line Combination Treatment with Durvalumab Plus Platinum and Etoposide Has Manageable Safety in ES-SCLC

(ESMO I-O 2019) Dec 12, 2019 - Results from analyses of safety, pharmacokinetics and immunogenecity in the CASPIAN trial.